March 24th 2023
Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
NCCN Guidelines Update Includes Injection for Cisplatin Ototoxicity in AYAs
February 14th 2023A medical oncologist and research audiologist from St. Jude Children’s Research Hospital discuss how sodium thiosulfate injection may improve quality of life by preventing cisplatin-associated ototoxicities in pediatric patients with localized non-metastatic tumors, although more research is needed.
Trilaciclib Prior to Sacituzumab Govitecan-hziy Appeared to Reduce AEs in Advanced TNBC
November 3rd 2022Initial findings from a phase 2 trial showed trilaciclib given before sacituzumab govitecan-hziy lessened the severity of adverse effects in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21st 2021A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.